December 2, 2024 06:39 AM ESTUpdated 09:41 AM

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

Ayisha Sharma

News Reporter

Merus said its bispecific antibody drug has standard-of-care potential in second-line and later head and neck cancer as it reported updated results from a mid …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Novocure says electric field therapy extends life for pancreatic cancer patients by two months

Senti Bio’s Phase 1 CAR-NK data; Allink raises $42M

Merus drug shows ‘un­ex­pect­ed im­prove­ment’ in sec­ond-line head and neck can­cer study

Ayisha Sharma

News Reporter

Sign up to read this article for free.

more like this

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Novo­cure says elec­tric field ther­a­py ex­tends life for pan­cre­at­ic can­cer pa­tients by two months

Sen­ti Bio’s Phase 1 CAR-NK da­ta; Allink rais­es $42M

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Novocure says electric field therapy extends life for pancreatic cancer patients by two months

Senti Bio’s Phase 1 CAR-NK data; Allink raises $42M